In this video, Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, briefly shares some insights on minimal residual disease (MRD)-directed therapy, highlighting the impact of autologous stem cell transplant (ASCT) on MRD negativity rates in the MASTER trial (NCT03224507) and the FORTE trial (NCT02203643). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.